Inhalation Sciences Sweden (NGM:ISAB) - Aandelenkoers, Nieuws & Analyse

ISAB Overzicht aandelen

Inhalation Sciences Sweden AB (publ) develops and sells labtech equipment for inhalation research. Meer informatie

ISAB fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 59.53% per jaar groeien

Handelen tegen een goede waarde vergeleken met branchegenoten en branchegenoten

Risicoanalyse

Aandelen zijn zeer illiquide

Heeft geen betekenisvolle marktkapitalisatie ( SEK66M )

De winst is de afgelopen 5 jaar met 17.9% per jaar gedaald

Aandeelhouders zijn het afgelopen jaar verwaterd

+ 1 meer risico

Inhalation Sciences Sweden AB (publ) Concurrenten

AroCell

OM:AROC

SEK 93.5m

Level Bio

NGM:LEVBIO

SEK 19.0m

PExA

NGM:PEXA B

SEK 17.1m

Magle Chemoswed Holding

OM:MAGLE

SEK 599.9m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Inhalation Sciences Sweden
Historische aandelenkoersen
Huidige aandelenkoers	SEK 4.34
52 Week Hoogtepunt	SEK 4.99
52 Week Laag	SEK 2.43
Bèta	0.52
11 maand verandering	0%
3 maanden verandering	6.90%
1 Jaar Verandering	24.36%
33 jaar verandering	-56.07%
5 jaar verandering	-43.86%
Verandering sinds IPO	-53.08%

Recent nieuws en updates

Recent updates

We're Not Counting On Inhalation Sciences Sweden (NGM:ISAB) To Sustain Its Statutory Profitability

Dec 29

Rendement voor aandeelhouders

	ISAB	SE Life Sciences	SE Markt
7D	0%	3.4%	0.1%
1Y	24.4%	25.3%	11.8%

Rendement versus industrie: ISAB overtrof de Swedish Life Sciences industrie, die het afgelopen jaar een rendement 25.3 % opleverde.

Rendement versus markt: ISAB overtrof de Swedish markt, die het afgelopen jaar een rendement opleverde van 11.8 %.

Prijsvolatiliteit

Is ISAB's price volatile compared to industry and market?
ISAB volatility
ISAB Average Weekly Movement	n/a
Life Sciences Industry Average Movement	7.3%
Market Average Movement	5.5%
10% most volatile stocks in SE Market	11.2%
10% least volatile stocks in SE Market	3.3%

Stabiele aandelenkoers: ISAB heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van ISAB in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2004	8	Manoush Masarrat	www.inhalation.se

Inhalation Sciences Sweden AB (publ) Samenvatting

Hoe verhouden de winst en inkomsten van Inhalation Sciences Sweden zich tot de beurswaarde?
ISAB fundamentele statistieken
Marktkapitalisatie	SEK 65.83m
Inkomsten(TTM)	-SEK 4.74m
Inkomsten(TTM)	SEK 17.50m

3.8x

P/S-verhouding

-13.9x

Koers/Winstverhouding

Is ISAB overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ISAB resultatenrekening (TTM)
Inkomsten	SEK 17.50m
Kosten van inkomsten	SEK 3.54m
Brutowinst	SEK 13.96m
Overige uitgaven	SEK 18.71m
Inkomsten	-SEK 4.74m

Laatst gerapporteerde inkomsten

Dec 31, 2023

Volgende inkomensdatum

May 28, 2024

Winst per aandeel (EPS)	-0.31
Brutomarge	79.77%
Nettowinstmarge	-27.10%
Schuld/Eigen Vermogen Verhouding	8.4%

Hoe presteerde ISAB op de lange termijn?

Bekijk historische prestaties en vergelijking

ISAB Overzicht aandelen

Beloningen

Risicoanalyse

Inhalation Sciences Sweden AB (publ) Concurrenten

OM:AROC

SEK 93.5m

NGM:LEVBIO

SEK 19.0m

NGM:PEXA B

SEK 17.1m

OM:MAGLE

SEK 599.9m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Inhalation Sciences Sweden AB (publ) to Report Nine Months, 2024 Results on Nov 20, 2024

Inhalation Sciences Sweden AB (publ) to Report Q2, 2024 Results on Aug 28, 2024

Inhalation Sciences Sweden AB (publ) to Report Q1, 2024 Results on May 28, 2024

Inhalation Sciences Sweden AB (publ), Annual General Meeting, May 14, 2024

Inhalation Sciences Sweden AB (publ) to Report Fiscal Year 2023 Results on Feb 28, 2024

Third quarter 2023 earnings released: kr0.098 loss per share (vs kr0.31 loss in 3Q 2022)

Recent updates

Inhalation Sciences Sweden AB (publ) to Report Nine Months, 2024 Results on Nov 20, 2024

Inhalation Sciences Sweden AB (publ) to Report Q2, 2024 Results on Aug 28, 2024

Inhalation Sciences Sweden AB (publ) to Report Q1, 2024 Results on May 28, 2024

Inhalation Sciences Sweden AB (publ), Annual General Meeting, May 14, 2024

Inhalation Sciences Sweden AB (publ) to Report Fiscal Year 2023 Results on Feb 28, 2024

Third quarter 2023 earnings released: kr0.098 loss per share (vs kr0.31 loss in 3Q 2022)

New major risk - Share price stability

Inhalation Sciences Sweden AB (publ) to Report Q3, 2023 Results on Nov 22, 2023

New major risk - Revenue and earnings growth

Inhalation Sciences Sweden AB (publ) to Report Q2, 2023 Results on Aug 29, 2023

New minor risk - Shareholder dilution

First quarter 2023 earnings released: kr0.20 loss per share (vs kr0.30 loss in 1Q 2022)

Inhalation Sciences Receives Formal Clearance to Begin the Trial of Inhalation Study

Inhalation Sciences Sweden AB (publ) to Report Fiscal Year 2022 Results on Feb 28, 2023

Third quarter 2022 earnings released: kr0.31 loss per share (vs kr0.40 loss in 3Q 2021)

No independent directors

Second quarter 2022 earnings released: kr0.36 loss per share (vs kr0.56 loss in 2Q 2021)

Inhalation Sciences Sweden AB (publ) Announces Resignation of Klaus Gottwald from Its Board of Directors

Inhalation Sciences Receives Landmark FDA Approval for Co-Financing of its Study to Validate Dissolvit as a Standard Research Method in the US

First quarter 2022 earnings: EPS and revenues miss analyst expectations

No independent directors

Full year 2021 earnings: EPS and revenues miss analyst expectations

Inhalation Sciences Sweden AB (publ), Annual General Meeting, May 06, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Inhalation Sciences Submits Whitepaper to FDA Aiming to Establish DissolvIt® as an FDA-Recommended Standard Research Method in US

Inhalation Sciences Announces Positive Study Results

Second quarter 2021 earnings released: kr0.56 loss per share (vs kr1.92 profit in 2Q 2020)

Investor sentiment improved over the past week

Inhalation Sciences Completes Enrolment in PreciseInhale Clinical Trial

Inhalation Sciences Sweden AB (Publ) Receives CTA Approval for Landmark Clinical Trial of Preciseinhale

Investor sentiment improved over the past week

First quarter 2021 earnings released: kr0.40 loss per share (vs kr0.068 profit in 1Q 2020)

Inhalation Sciences AB Provides Revenue Guidance for the Full Year of Fiscal 2021

New 90-day low: kr10.30

We're Not Counting On Inhalation Sciences Sweden (NGM:ISAB) To Sustain Its Statutory Profitability

Inhalation Sciences Appoints Paolo Raffaelli as New Chief Commercial Officer to Drive Global Sales

Market bids up stock over the past week

Inhalation Sciences Receives New Order Worth EUR 196,000 from University of Vienna

New 90-day low: kr10.80

Inhalation Sciences Announces to Successfully Installed its First Ever Commercial Version of the in Vitro Dissolvit Module at the Swiss Laboratory of a Long-Term ISAB Customer

An undisclosed buyer acquired an unknown stake in Ziccum AB (publ) (NGM:ZICC) from Inhalation Sciences Sweden AB (publ) (NGM:ISAB) for approximately SEK 21.2 million.